Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates ofPseudomonas aeruginosa
Explore this paper's citation graph
Summary
The in vitro activity of a new parenteral cephalosporin cefepime (BMY 28142) was compared with that of ceftazidime, superior to that of cefotaxime, piperacillin, gentamicin and amikacin, but inferior to those of imipenem and ciprofloxacin.
- Type
- article
- Published
- 1989-10-01
- Cited by
- 0
- References
- 16
- OpenAlex
- https://openalex.org/W2013671604
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8663473
Keywords
Cefepime, Microbiology, Medical microbiology, In vitro, Medicine
References
- Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins
- In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin
- Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics
- In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum
- Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy
- New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits
- Synergistic resistance mechanisms in Pseudomonas aeruginosa.
- Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime
- Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci
- In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents
- Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin
- Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.
- Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
- Nosocomial consequences of antibiotic usage.
Cited by
No citing papers recorded for this paper.
Related papers
- An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response.
- Cefepime Resistance and Associated Risk Factors among Escherichia coli Strains Isolated from Clinical Specimens
- Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical Isolate
- Susceptibility of Pseudomonas aeruginosa to Cefepime versus Ceftazidime in Patients with Cystic Fibrosis
- Neurotoxicity by Cefepime: Case-Control Study
- Neurotoxicity by Cefepime: Case-Control Study
- Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
- The Trend of Cefepime-Induced Neurotoxicity: A Systematic Review
- Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study